Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic equivalence of intramuscular vs subcutaneous Pamorelin LA 11.25 mg in advanced prostate cancer
2010-019632-12Phase 2Completed
- Sponsor
- Ipsen
- Start
- Aug 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Pamorelin in prostate cancer (PCa) (2 arms), sponsored by Ipsen. Primary endpoint: Area under the curve of testosterone serum concentration between Day 1 and Day 85 (AUC1-85d). Started Aug 2010; status: completed.
02
Drugs
Pamorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-019632-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019632-12.